May 09, 2018
AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
May 09, 2018
AcelRx resubmits New Drug Application for DSUVIA(TM)
Apr 30, 2018
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
Apr 27, 2018
AcelRx receives positive CHMP opinion for DZUVEO(TM) for management of acute moderate to severe pain in medically monitored settings
Apr 25, 2018
AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018
Apr 18, 2018
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
Apr 16, 2018
AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
Apr 11, 2018
AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
Mar 27, 2018
AcelRx announces appointment of John Saia as General Counsel
Mar 08, 2018
AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results
Mar 08, 2018
AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018
Mar 05, 2018
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March
Nov 16, 2017
AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain
Nov 09, 2017
AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results
Nov 09, 2017
AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department
Oct 30, 2017
AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 9th
Oct 20, 2017
AcelRx's DSUVIA(TM) Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017
Oct 12, 2017
AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA(TM) NDA
Sep 06, 2017
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
Aug 01, 2017
AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update